Business Context and Reporting Period
This Form 8-K is a current report filed by Lisata Therapeutics, Inc. on April 15, 2026. The filing addresses Item 8.01 (Other Events) regarding an extension of the deadline to commence a tender offer under a previously announced Merger Agreement dated March 6, 2026, with Kuva Labs Inc. (Parent) and its subsidiary Kuva Acquisition Corp. (Purchaser).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on the status of the proposed acquisition and tender offer timeline.
Material Changes Versus Prior Period
- Extension of Tender Offer Deadline: The date by which the Purchaser is obligated to commence the tender offer for all outstanding shares of Lisata common stock has been extended from April 3, 2026 to April 13, 2026.
- Financing Status: The Purchaser has not yet commenced the tender offer. The Parent is currently seeking alternative sources of financing on terms more favorable to the Parent to fund the transaction.
- Current Status: The Company and Parent are in discussions regarding financing and the timing of the tender offer commencement.
Guidance, Outlook, Risks, and Contingencies
Outlook and Uncertainty: There is no assurance as to when the tender offer will commence, if at all. The transaction is contingent upon the Parent finalizing financing.
Material Risks and Contingencies:
- Termination Risk: Failure to commence the tender offer by April 13, 2026, or other events could lead to the termination of the Merger Agreement, potentially triggering termination fees.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the acquisition, timetable, and future performance, which are subject to significant risks and uncertainties.
- Operational Risks: Risks include the ability to complete the transaction, stockholder tendering rates, potential competing offers, legal proceedings, employee retention issues, and the inherent uncertainties of Lisata's clinical-stage operations and product development.
- Regulatory and Clinical Risks: Success depends on demonstrating efficacy and safety of product candidates and obtaining regulatory approval.
Investor Action: Investors are urged to read the future Schedule TO (tender offer statement) and Schedule 14D-9 (solicitation/recommendation statement) when filed, as they will contain critical information for decision-making.
Important Facts for Investor Verification
- Verify the finalization of financing by Kuva Labs Inc. to determine if the tender offer will proceed.
- Monitor the April 13, 2026 deadline for the commencement of the tender offer to assess termination risks.
- Review upcoming SEC filings (Schedule TO and Schedule 14D-9) for definitive offer terms and recommendations.
- Assess the impact of the extended timeline on Lisata's cash runway and operational continuity.
- Confirm whether any termination fees are payable under the Merger Agreement if the transaction fails to close.